Literature DB >> 30115681

Mechanism of dysfunction of human variants of the IRAK4 kinase and a role for its kinase activity in interleukin-1 receptor signaling.

Saurav De1, Fawziya Karim1, Ezechielle Kiessu1, Leah Cushing1, Lih-Ling Lin1, Pegah Ghandil2,3, Cyrille Hoarau4, Jean-Laurent Casanova5,6,7,8,9, Anne Puel5,6,8, Vikram R Rao10.   

Abstract

Interleukin-1 receptor (IL1R)-associated kinase 4 (IRAK4) is a central regulator of innate immune signaling, controlling IL1R and Toll-like receptor (TLR)-mediated responses and containing both scaffolding and kinase activities. Humans deficient in IRAK4 activity have autosomal recessive primary immune deficiency (PID). Here, we characterized the molecular mechanism of dysfunction of two IRAK4 PID variants, G298D and the compound variant R12C (R12C/R391H/T458I). Using these variants and the kinase-inactive D329A variant to delineate the contributions of IRAK4's scaffolding and kinase activities to IL1R signaling, we found that the G298D variant is kinase-inactive and expressed at extremely low levels, acting functionally as a null mutation. The R12C compound variant possessed WT kinase activity, but could not interact with myeloid differentiation primary response 88 (MyD88) and IRAK1, causing impairment of IL-1-induced signaling and cytokine production. Quantitation of IL-1 signaling in IRAK4-deficient cells complemented with either WT or the R12C or D329A variant indicated that the loss of MyD88 interaction had a greater impact on IL-1-induced signaling and cytokine expression than the loss of IRAK4 kinase activity. Importantly, kinase-inactive IRAK4 exhibited a greater association with MyD88 and a weaker association with IRAK1 in IRAK4-deficient cells expressing kinase-inactive IRAK4 and in primary cells treated with a selective IRAK4 inhibitor. Loss of IRAK4 kinase activity only partially inhibited IL-1-induced cytokine and NF-κB signaling. Therefore, the IRAK4-MyD88 scaffolding function is essential for IL-1 signaling, but IRAK4 kinase activity can control IL-1 signal strength by modulating the association of IRAK4, MyD88, and IRAK1.
© 2018 De et al.

Entities:  

Keywords:  Toll/interleukin-1 receptor (TIR); cell signaling; cytokine; inflammation; innate immunity; interleukin 1 (IL-1); interleukin-1 receptor-associated kinase 4 (IRAK4); myeloid differentiation primary response gene 88 (MyD88); protein kinase

Mesh:

Substances:

Year:  2018        PMID: 30115681      PMCID: PMC6166721          DOI: 10.1074/jbc.RA118.003831

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  20 in total

1.  Interleukin 1/Toll-like receptor-induced autophosphorylation activates interleukin 1 receptor-associated kinase 4 and controls cytokine induction in a cell type-specific manner.

Authors:  Leah Cushing; Wayne Stochaj; Marshall Siegel; Robert Czerwinski; Ken Dower; Quentin Wright; Margaret Hirschfield; Jean-Laurent Casanova; Capucine Picard; Anne Puel; Lih-Ling Lin; Vikram R Rao
Journal:  J Biol Chem       Date:  2014-02-24       Impact factor: 5.157

2.  Clinical features and outcome of patients with IRAK-4 and MyD88 deficiency.

Authors:  Capucine Picard; Horst von Bernuth; Pegah Ghandil; Maya Chrabieh; Ofer Levy; Peter D Arkwright; Douglas McDonald; Raif S Geha; Hidetoshi Takada; Jens C Krause; C Buddy Creech; Cheng-Lung Ku; Stephan Ehl; László Maródi; Saleh Al-Muhsen; Sami Al-Hajjar; Abdulaziz Al-Ghonaium; Noorbibi K Day-Good; Steven M Holland; John I Gallin; Helen Chapel; David P Speert; Carlos Rodriguez-Gallego; Elena Colino; Ben-Zion Garty; Chaim Roifman; Toshiro Hara; Hideto Yoshikawa; Shigeaki Nonoyama; Joseph Domachowske; Andrew C Issekutz; Mimi Tang; Joanne Smart; Simona Eva Zitnik; Cyrille Hoarau; Dinakantha S Kumararatne; Adrian J Thrasher; E Graham Davies; Claire Bethune; Nicolas Sirvent; Dominique de Ricaud; Yildiz Camcioglu; Júlia Vasconcelos; Margarida Guedes; Artur Bonito Vitor; Carlos Rodrigo; Francisco Almazán; Maria Méndez; Juan Ignacio Aróstegui; Laia Alsina; Claudia Fortuny; Janine Reichenbach; James W Verbsky; Xavier Bossuyt; Rainer Doffinger; Laurent Abel; Anne Puel; Jean-Laurent Casanova
Journal:  Medicine (Baltimore)       Date:  2010-11       Impact factor: 1.889

3.  IRAK4 kinase activity controls Toll-like receptor-induced inflammation through the transcription factor IRF5 in primary human monocytes.

Authors:  Leah Cushing; Aaron Winkler; Scott A Jelinsky; Katherine Lee; Wouter Korver; Rachael Hawtin; Vikram R Rao; Margaret Fleming; Lih-Ling Lin
Journal:  J Biol Chem       Date:  2017-09-18       Impact factor: 5.157

4.  Functional assessment of the mutational effects of human IRAK4 and MyD88 genes.

Authors:  Takahiro Yamamoto; Naotaka Tsutsumi; Hidehito Tochio; Hidenori Ohnishi; Kazuo Kubota; Zenichiro Kato; Masahiro Shirakawa; Naomi Kondo
Journal:  Mol Immunol       Date:  2013-12-05       Impact factor: 4.407

Review 5.  Recent advances in the discovery of small molecule inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4) as a therapeutic target for inflammation and oncology disorders.

Authors:  Divya Chaudhary; Shaughnessy Robinson; Donna L Romero
Journal:  J Med Chem       Date:  2014-12-05       Impact factor: 7.446

6.  The kinase activities of interleukin-1 receptor associated kinase (IRAK)-1 and 4 are redundant in the control of inflammatory cytokine expression in human cells.

Authors:  Kyung W Song; Francisco X Talamas; Rebecca T Suttmann; Pam S Olson; Jim W Barnett; Simon W Lee; Kelly D Thompson; Sue Jin; Mohammad Hekmat-Nejad; Terrence Z Cai; Anthony M Manning; Ronald J Hill; Brian R Wong
Journal:  Mol Immunol       Date:  2009-01-31       Impact factor: 4.407

7.  Helical assembly in the MyD88-IRAK4-IRAK2 complex in TLR/IL-1R signalling.

Authors:  Su-Chang Lin; Yu-Chih Lo; Hao Wu
Journal:  Nature       Date:  2010-05-19       Impact factor: 49.962

8.  Human Adaptive Immunity Rescues an Inborn Error of Innate Immunity.

Authors:  Laura Israel; Ying Wang; Katarzyna Bulek; Erika Della Mina; Zhao Zhang; Vincent Pedergnana; Maya Chrabieh; Nicole A Lemmens; Vanessa Sancho-Shimizu; Marc Descatoire; Théo Lasseau; Elisabeth Israelsson; Lazaro Lorenzo; Ling Yun; Aziz Belkadi; Andrew Moran; Leonard E Weisman; François Vandenesch; Frederic Batteux; Sandra Weller; Michael Levin; Jethro Herberg; Avinash Abhyankar; Carolina Prando; Yuval Itan; Willem J B van Wamel; Capucine Picard; Laurent Abel; Damien Chaussabel; Xiaoxia Li; Bruce Beutler; Peter D Arkwright; Jean-Laurent Casanova; Anne Puel
Journal:  Cell       Date:  2017-02-23       Impact factor: 66.850

9.  Selective predisposition to bacterial infections in IRAK-4-deficient children: IRAK-4-dependent TLRs are otherwise redundant in protective immunity.

Authors:  Cheng-Lung Ku; Horst von Bernuth; Capucine Picard; Shen-Ying Zhang; Huey-Hsuan Chang; Kun Yang; Maya Chrabieh; Andrew C Issekutz; Coleen K Cunningham; John Gallin; Steven M Holland; Chaim Roifman; Stephan Ehl; Joanne Smart; Mimi Tang; Franck J Barrat; Ofer Levy; Douglas McDonald; Noorbibi K Day-Good; Richard Miller; Hidetoshi Takada; Toshiro Hara; Sami Al-Hajjar; Abdulaziz Al-Ghonaium; David Speert; Damien Sanlaville; Xiaoxia Li; Frédéric Geissmann; Eric Vivier; László Maródi; Ben-Zion Garty; Helen Chapel; Carlos Rodriguez-Gallego; Xavier Bossuyt; Laurent Abel; Anne Puel; Jean-Laurent Casanova
Journal:  J Exp Med       Date:  2007-09-24       Impact factor: 14.307

10.  The mechanism of activation of IRAK1 and IRAK4 by interleukin-1 and Toll-like receptor agonists.

Authors:  Stefan Vollmer; Sam Strickson; Tinghu Zhang; Nathanael Gray; Katherine L Lee; Vikram R Rao; Philip Cohen
Journal:  Biochem J       Date:  2017-06-06       Impact factor: 3.857

View more
  8 in total

1.  Dimethyl Fumarate Disrupts Human Innate Immune Signaling by Targeting the IRAK4-MyD88 Complex.

Authors:  Balyn W Zaro; Ekaterina V Vinogradova; Daniel C Lazar; Megan M Blewett; Radu M Suciu; Junichiro Takaya; Sean Studer; Juan Carlos de la Torre; Jean-Laurent Casanova; Benjamin F Cravatt; John R Teijaro
Journal:  J Immunol       Date:  2019-03-18       Impact factor: 5.422

2.  [Mechanism of ulinastatin in reducing lung inflammatory injury in rats with hemorrhagic shock].

Authors:  Ying Chen; Zhipeng Xu; Qi Song; Zhenjie Wang; Zhong Ji; Zhaolei Qiu; Feng Cheng; Hai Jiang
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2019-10-30

3.  Design, Synthesis, and Biological Evaluation of IRAK4-Targeting PROTACs.

Authors:  Yun Chen; Yi Ning; Gang Bai; Linjiang Tong; Tao Zhang; Jinpei Zhou; Huibin Zhang; Hua Xie; Jian Ding; Wenhu Duan
Journal:  ACS Med Chem Lett       Date:  2020-12-10       Impact factor: 4.345

Review 4.  Protein phosphatases in TLR signaling.

Authors:  Clovis H T Seumen; Tanja M Grimm; Christof R Hauck
Journal:  Cell Commun Signal       Date:  2021-04-21       Impact factor: 5.712

5.  The Interleukin-1 Receptor-Associated Kinase 4 Inhibitor PF-06650833 Blocks Inflammation in Preclinical Models of Rheumatic Disease and in Humans Enrolled in a Randomized Clinical Trial.

Authors:  Aaron Winkler; Weiyong Sun; Saurav De; Aiping Jiao; M Nusrat Sharif; Peter T Symanowicz; Shruti Athale; Julia H Shin; Ju Wang; Bruce A Jacobson; Simeon J Ramsey; Ken Dower; Tatyana Andreyeva; Heng Liu; Martin Hegen; Bruce L Homer; Joanne Brodfuehrer; Mera Tilley; Steven A Gilbert; Spencer I Danto; Jean J Beebe; Betsy J Barnes; Virginia Pascual; Lih-Ling Lin; Iain Kilty; Margaret Fleming; Vikram R Rao
Journal:  Arthritis Rheumatol       Date:  2021-11-01       Impact factor: 15.483

6.  Effects of adenovirus-mediated knockdown of IRAK4 on synovitis in the osteoarthritis rabbit model.

Authors:  Muzhe Li; Huiyun Li; Xun Ran; Han Yin; Xuling Luo; Zhiwei Chen
Journal:  Arthritis Res Ther       Date:  2021-12-04       Impact factor: 5.156

7.  The IRAK4 scaffold integrates TLR4-driven TRIF and MYD88 signaling pathways.

Authors:  Milton Pereira; Danielle F Durso; Clare E Bryant; Evelyn A Kurt-Jones; Neal Silverman; Douglas T Golenbock; Ricardo T Gazzinelli
Journal:  Cell Rep       Date:  2022-08-16       Impact factor: 9.995

Review 8.  Kinase inhibition in autoimmunity and inflammation.

Authors:  Ali A Zarrin; Katherine Bao; Patrick Lupardus; Domagoj Vucic
Journal:  Nat Rev Drug Discov       Date:  2020-10-19       Impact factor: 84.694

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.